Sangamo Therapeutics, Inc. (SGMO) Position Boosted by Vanguard Group Inc

Among 9 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 4 have Buy rating, 1 Sell and 4 Hold. (SGMO) on Thursday reported a loss of $12.4 million in its third quarter. The Firm has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. Jefferies Group LLC reaffirmed a "buy" rating and set a $18.00 price target on shares of Sangamo Therapeutics in a research note on Friday, October 13th. Swiss National Bank boosted its stake in shares of Sangamo Therapeutics by 26.4% during the 2nd quarter. The company had a trading volume of 3,081,560 shares, compared to its average volume of 1,287,012.

"Based on the progress we've made this year, our board of directors has encouraged us to be bold in planning for the company's successful future", said Sandy Macrae, CEO of Sangamo.

Frontier Capital Com Ltd Liability owns 495,028 shares or 0.03% of their USA portfolio. About 563,558 shares traded. The portion of a company's profit allocated to each outstanding share of common stock was $0.48 a share in the trailing twelve months.

Sangamo Therapeutics, Inc. has a beta of 1.04, offering the possibility of a higher rate of return, but also posing more risk. Schwab Charles Investment Management Inc. now owns 265,735 shares of the biopharmaceutical company's stock valued at $1,382,000 after buying an additional 14,022 shares during the period.

At the moment, the top institutional investor at Sangamo Therapeutics, Inc. $13's average target is -3.35% below currents $13.45 stock price. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

The most recent insider trade was by a Officer named HERBERTS CURT A. III, and it was an direct of 15000 shares - leaving the insider with 15833 shares after the transaction. The shares were sold at an average price of $15.00, for a total transaction of $225,000.00. Institutional investors own 62.24% of the company's stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 72,474 shares of company stock valued at $1,019,009. Barrington Research maintained it with "Outperform" rating and $68 target in Friday, May 13 report. The rating was maintained by Jefferies on Tuesday, September 12 with "Buy". The rating was reinitiated by Jefferies with "Buy" on Friday, October 23. Dentsply International had 40 analyst reports since August 3, 2015 according to SRatingsIntel. The stock of Sangamo Therapeutics Inc (NASDAQ:SGMO) earned "Hold" rating by Piper Jaffray on Thursday, August 10. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has "Hold" rating by Wedbush on Monday, August 14. Wells Fargo & Company MN raised its stake in Sangamo Therapeutics by 45.8% during the second quarter. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.23) by $0.06. For the quarter ending Mar-18, 4 analysts have a mean sales target of 8.30 million whilst for the year ending Dec-17, 5 analysts have a mean target of 33.24 million.

Sangamo BioSciences (NASDAQ:SGMO) last announced its quarterly earnings results on Wednesday, October 26th. Currently, 112.13 million total shares are owned by the public and among those 0 million shares have been available to trade. Sangamo Therapeutics (NASDAQ:SGMO) has a Return on Assets (ROA) of -30.7. During the same period a year ago, the company earned ($0.38) EPS. Sangamo Therapeutics's quarterly revenue was up 333.0% compared to the same quarter last year. equities research analysts expect that Sangamo Therapeutics, Inc. will post -0.85 EPS for the current fiscal year.